Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients

被引:21
|
作者
Toth, Kinga [1 ]
Patai, Arpad V. [1 ]
Kalmar, Alexandra [1 ,2 ]
Bartak, Barbara Kinga [1 ]
Nagy, Zsofia Brigitta [1 ]
Galamb, Orsolya [2 ]
Wichmann, Barnabas [2 ]
Tulassay, Zsolt [1 ,2 ]
Molnar, Bela [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi Utca 46, H-1088 Budapest, Hungary
[2] Hungarian Acad Sci, Mol Med Res Unit, Budapest, Hungary
关键词
SEPT9; Colorectal cancer; Tumormarkers; Circadian rhythm; Cell-free DNA; BREAST-CANCER; CLOCK; PLASMA; BLOOD; PROGRESSION; EXERCISE; INFLAMMATION; CORTISOL; BEHAVIOR; SLEEP;
D O I
10.1007/s12253-016-0174-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19-9, TPA, CA72-4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43-48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19-9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 50 条
  • [1] Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients
    Yang, Xue
    Xu, Zhi-Jie
    Chen, Xi
    Zeng, Shuang-Shuang
    Qian, Long
    Wei, Jie
    Peng, Mei
    Wang, Xiang
    Liu, Wan-Li
    Ma, Hong-Ying
    Gong, Zhi-Cheng
    Yan, Yuan-Liang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (17) : 2099 - 2109
  • [2] Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma
    Salvianti, Francesca
    Orlando, Claudio
    Massi, Daniela
    De Giorgi, Vincenzo
    Grazzini, Marta
    Pazzagli, Mario
    Pinzani, Pamela
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2016, 2
  • [3] Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
    Fu, Bo
    Yan, Peng
    Zhang, Shan
    Lu, Yan
    Pan, Li
    Tang, Wenqiang
    Chen, Shen
    Chen, Shuangfeng
    Zhang, Anqi
    Liu, Wei
    DISEASE MARKERS, 2018, 2018
  • [4] Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer
    Philipp, Alexander B.
    Nagel, Dorothea
    Stieber, Petra
    Lamerz, Rolf
    Thalhammer, Isabel
    Herbst, Andreas
    Kolligs, Frank T.
    BMC CANCER, 2014, 14
  • [5] Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer
    Alexander B Philipp
    Dorothea Nagel
    Petra Stieber
    Rolf Lamerz
    Isabel Thalhammer
    Andreas Herbst
    Frank T Kolligs
    BMC Cancer, 14
  • [6] Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden
    Bhangu, Jagdeep Singh
    Taghizadeh, Hossein
    Braunschmid, Tamara
    Bachleitner-Hofmann, Thomas
    Mannhalter, Christine
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (04): : 395 - 401
  • [7] Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies
    Zhu, Mojun
    Taylor, William R.
    Mahoney, Douglas W.
    Then, Sara S.
    Berger, Calise K.
    Burger, Kelli N.
    Gonser, Anna M.
    Doering, Karen A.
    Xie, Hao
    Foote, Patrick H.
    Kaiser, Michael W.
    Allawi, Hatim T.
    Hubbard, Joleen M.
    Kisiel, John B.
    CANCERS, 2023, 15 (24)
  • [8] Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma
    Hu, Ying
    Chen, Yawei
    Guo, Hao
    Yu, Jianing
    Chen, Yanhui
    Liu, Yang
    Lan, Ling
    Li, Jian
    Wang, Huaqing
    Zhang, Henghui
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5159 - 5167
  • [9] Cancer stage-dependent alterations in cell-free DNA in patients with colorectal caner
    Pu, Wangyang
    Xiao, Li
    Zhou, Cuilan
    Zhong, Fengyun
    Wu, Yongyou
    Gong, Wei
    Lv, Xiaodong
    Zhuang, Zhixiang
    Wang, Hui
    Bian, Huahui
    Wang, Ji
    Zhang, Rong
    Li, Kai
    Xing, Chungen
    JOURNAL OF BUON, 2021, 26 (01): : 109 - 115
  • [10] LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer
    Nagai, Yuzo
    Sunami, Eiji
    Yamamoto, Yoko
    Hata, Keisuke
    Okada, Satoshi
    Murono, Koji
    Yasuda, Koji
    Otani, Kensuke
    Nishikawa, Takeshi
    Tanaka, Toshiaki
    Kiyomatsu, Tomomichi
    Kawai, Kazushige
    Nozawa, Hiroaki
    Ishihara, Soichiro
    Hoon, Dave S. B.
    Watanabe, Toshiaki
    ONCOTARGET, 2017, 8 (07) : 11906 - 11916